ORLANDO, FL — May 20, 2002 —
Patients who received a docetaxel-based treatment for adjuvant therapy of node positive breast cancer rather than a 5-flourouracil-based treatment achieved an 32 percent reduction in risk of developing recurrent cancer.
Researchers said that after three years the disease free survival from patients on a regimen of docetaxel, doxorubicin and cyclophosphamide (TAC) was 82 percent. For patients on the current commonly used regimen of 5-FU, doxorubicin and cyclophosphamide (FAC) the three-year disease-free survival was 72 percent. “That represents an absolute difference of 8 percent,” said Jean-Marc Nabholtz, MD, professor of medicine at the University of California at Los Angeles.
The difference was statistically significant to the p=0.0011 level, he said here Sunday at the 38th annual meeting of the American Society of Clinical Oncology (ASCO). The Phase III trail comparing the two therapies enrolled 1,491 patients who were randomly assigned to either of the treatment modalities. The patients received six cycles of treatment and 94 percent of the patients were able to complete the chemotherapy regimen. Dr. Nabholtz said the researchers observed 119 events in TAC group compared with 170 events in FAC group.
The cohort was also scrutinized to determine if the number of positive lymph nodes resulted in an outcome difference. Dr. Nabholtz said that women on TAC with one to three positive nodes achieved a 52 percent reduction in events compared with women with one to three nodes who had received FAC. However, among women with four or more positive lymph nodes there was no statistically significant difference in events.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!